Placeholder Banner

BIO Participating in IDSA Stakeholder Group on Antimicrobial Resistance

September 5, 2014
BIO will be participating in a newly formed partnership which will work collaboratively to inform federal policy and find ways to better combat the growing crisis of antimicrobial resistance. Launched yesterday by the Infectious Diseases Society of America (IDSA), which also released foundation principles for the group, the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR) will hold its inaugural meeting in Philadelphia next month on October 9th.

BIO joins more than 75 other national organizations in the Forum, which thus far includes representatives from medical and allied health professionals, hospitals, patients and consumers, public health, research and advocacy, and industry, including pharmaceutical and biotechnology companies.

S-FAR is being formed a time of growing recognition that new efforts are needed to combat antimicrobial resistance. The President’s Council of Advisors on Science and Technology is expected to recommend more federal coordination on the problem in an upcoming report. S-FAR will facilitate engagement with federal policy makers and the diverse set of stakeholders involved in antimicrobial resistance, including biotechnology companies working to develop new and more effective treatments.

According to the IDSA press release, S-FAR supports the following principles:

  • Antimicrobial resistance (AR) is a well-documented and urgent problem of global significance and the U.S. should be a leader in a multi-pronged effort to reduce the negative impact of resistance on human, animal, and plant health.

  • The U.S. needs a financed, coordinated, actionable national plan to address AR with measurable goals, timelines, and mechanisms for accountability.

  • The U.S. AR action plan and its implementation must be informed by formal, substantive, and regular engagement with non-government experts and stakeholders.

  • Government alone cannot effectively address the problem of AR; stakeholders (including healthcare providers, pharmacists, veterinarians, patients and their families, consumers, payers, public health entities, industry, farmers & ranchers, researchers and academia, advocates, and others) are critical partners who can help inform policy, create awareness, and mobilize key constituencies and the broader public to support action.